Bernard A. Fox, Co-Founder / President / CEO at UbiVac, posted on X:
“Heading to AACR2025 in Chicago to talk about our work on combination cancer immunotherapy for HNSCC and see what is exciting scientists from across the globe.
Also looking forward to visiting the Loyola University Chicago Cancer Center to talk with Prof. Michael Nishimura regarding TCR.”